Clinical Efficacy and Safety of Mist Nibima & Lucky Herbal Mixture: Two (2) Ghanaian Herbal Anti-malarial Formulations.

Department of Biomedical Sciences0 个研究点目标入组 75 人开始时间: 2021年6月24日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients to be included in this study will comprise:
•Male and females between the ages of 18-65 years.
•Such patients should also have a fever, defined as >37.5ºC, during the current illness, or history (within the last 48 hours) of fever.
•They should also have been diagnosed with malaria defined as blood parasitemia = 200 parasites/µl.
•Participants should be able to communicate well with the investigator, comply with the requirements of the entire study, willing and/or able to return for a follow up and provide a written informed consent to participate as shown by a signature or thumbprint on the informed consent form.

•Patients accessed by the clinician to be at risk of developing severe malaria or those with the signs and symptoms including but not limited to:
•impaired consciousness or unrousable coma, prostration, i.e. generalized weakness so that the patient is unable walk or sit up without assistance, failure to feed, multiple convulsions, deep breathing, respiratory distress (acidotic breathing), circulatory collapse or shock, systolic blood pressure < 70 mm Hg in adults and < 50 mm Hg in children and clinical jaundice plus evidence of other vital organ dysfunction will all be excluded from the study.
•Also, to be excluded are pregnant and lactating mothers, infants and newborns.
•Individuals with chronic diseases of the liver, renal system, as well as those who are on any antimalarials or have done so within the last 2 weeks will be excluded from this study.

发起方

Department of Biomedical Sciences